Moderna’s Flu Vaccine Shows Positive Late-Stage Trial Results
- By BSTQ Staff
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
In May, Moderna voluntarily withdrew an application seeking approval of its combination vaccine targeting COVID-19 and influenza, saying it had plans to resubmit it with efficacy data from the Phase III trial on its stand-alone flu vaccine.
According to Stephen Hoge, the company’s head of research and development, with the new data, the company plans to resubmit the application for the combination vaccine and file for approval of its stand-alone flu vaccine later this year.
If regulators approve the flu vaccine, the company can then advance the combination vaccine, Hoge said. He added that Moderna expects approvals for both shots next year pending reviews.
References
Constantino, AK. Moderna’s Flu Vaccine Shows Positive Late-Stage Trial Results, Paving Way for Combination Covid Shot. CNBC, June 30, 2025. Accessed at www.cnbc.com/2025/06/30/modernas-flu-vaccine-shows-positive-trial-results-paving-way-for-combo-shot.html.
